World's Wealthiest Comparison— 1. Elon Musk: $1.1 trillion 2-5. Larry Page Sergey Brin Jeff Bezos Larry Ellison: $1.08 trillion Insanity.

I take Cialis, but not for sex. It’s actually a longevity medicine. Cialis (Tadalafil) is great for the same reason it gives you fantastic erections… it improves blood flow. Studies show that Tadalafil… 34% reduced all-cause mortality 27% reduced major heart disease 34% reduced stroke 32% reduced dementia It has also shown benefit in insulin sensitivity, metabolic health, and reduction of body fat. Women have blood vessels too, so theoretically they'd get the same longevity upside. The research is thinner, but early signals are promising. It’s sad that when men and women could benefit from it can miss out because it’s taboo. My protocol is 5mg daily and I've been on it for about two years. *Observational research shows associations, not causation. Outcomes may be influenced by underlying differences in study populations. This is not medical advice and is shared for informational purposes only.

the first TRILLIONAIRE in history

Switzerland to vote on plan to cap population at 10 million bbc.in/4xr0nHK

New Science Blog: Why has AI advanced faster in coding than in biology? To agents, bio databases are like cities built before cars—maddening to drive in because they're designed for different traffic. How do we build infrastructure agents can use? anthropic.com/research/agent…

Bill Gates needs to do three things right now: 1) fire his whole PR machine and stop trying to be admired 2) eat sh*t without nibbling 3) get out of the way of the technical work

Foundations of Gerophysics @MaxUnfried @fedichev @BKennedy_aging @AgingJrnl aging-us.com/article/206378/…

Massive output uptick due to agentic AI. Complete flat adoption.

In the United States, lung cancer is the leading cause of cancer death. Soon, that may change — a lung cancer vaccine has officially entered human trials. A groundbreaking global trial of the world's first mRNA lung cancer vaccine has officially launched, offering a personalized, targeted weapon against the deadliest form of the disease. Doctors have officially initiated human trials for BNT116, the world’s first mRNA lung cancer vaccine targeting non-small cell lung cancer (NSCLC), which is the most common and deadliest form of the disease. Developed by BioNTech, the investigational therapy utilizes the same messenger RNA technology that successfully powered COVID-19 vaccines. However, instead of fighting viruses, this jab is engineered to deliver precise genetic instructions that train the patient's immune system to identify and destroy tumor cells while sparing healthy surrounding tissues from the harsh side effects associated with traditional chemotherapy. The Phase 1 clinical trial is currently underway across 34 research sites in seven countries, including the United States and the United Kingdom, and is enrolling about 130 patients. Delivered via weekly doses followed by long-term maintenance injections, the vaccine is administered alongside immunotherapy to supercharge the body's natural defenses. Early participants, such as 67-year-old London scientist Janusz Racz, have already begun treatment. Researchers hope this proactive approach will not only eliminate existing tumors but also prevent the disease from recurring, potentially transforming the landscape of personalized oncology. source: University College London Hospitals NHS Foundation Trust. First UK patient receives innovative lung cancer vaccine.

Over the past few months, I've been collaborating with @socialcapital (@chamath's investment vehicle) on a two-part deep dive into the current state of Longevity Biotech and Aging Research. This deep dive aims to be a solid introduction to the field. It assumes no background in biology, medicine, or biotech. If you've been wondering what science knows about aging, what makes us believe aging can be slowed or reversed, or which companies are making real progress toward developing therapies against aging, this is for you! Part 1 is out now. It's a foundation for understanding the biology of aging and the current state of longevity biotech. Part 2 follows shortly, covering the strategies researchers, companies, and investors are pursuing to slow or reverse aging. Thank you, @chamath and @socialcapital team, for the opportunity to work with you on it. And thank you to all contributors who helped to make this deep dive objective and engaging, and who are making anti-aging interventions a reality: @Andrei_Tarkhov, @elimohamad, @fedichev, @KarlPfleger, @MarkHamalainen, @MartinBJensen, @MaxUnfried, @mkaeberlein, @omri_drory, @RaianyRomanni, @realnathancheng, @sebastiangiwa, @shappiron, @shoylev, @statto, @strygah, @ydeigin If any errors are to be found in this deep dive, I own them.